Megan Olsen, MPH, principal at Avalere, discusses the role that value assessments are expected to play in the future pricing of gene and cell therapies.
Megan Olsen, MPH, principal at Avalere, discusses how the impact of small patient populations and other limitations may influence payer conversations about gene and cell therapies.
Transcript
What role will value assessments play in payer decisions on pricing for cell and gene therapies?
It's going to play an important role. And I think it already is today, to some extent. We've done some survey research with payers at Avalere and found that most payers are already doing their own valuations for products in this space. We've also seen other entities like [the Institute for Clinical and Economic Review] be referenced as a key stakeholder at informing valuation of various products in this space. When you have an introduction of a high cost potentially million dollar therapy, with the potential for the benefit over many years, it's going to get a lot of attention you'll want to understand what is the true value of the product relative to price. So, there are a lot of different frameworks under consideration for how to measure that and how to adapt various methodologies or framework specific to the cell and gene therapies, given the uniqueness of the asset.
There's a lot of evolving in the value-based space in the private market, but also in the policy sphere as well. We're seeing the new Biden administration emerge with its priorities in health care and I think value-based care is going to be at the top and we've heard references in the drug pricing arena on interest in tying prices to value in some way or leveraging or standing up a value assessment entity to really measure value and potentially have a role in informing price as well. So, I think a lot more to come there. And this whole swirling interest in innovative financing models is based on value and wanting to determine net pricing based on the value that the product is delivering to the patient, to the health care system, to the payer, etc. So, needing that data to to make those determinations but also using the data that is derived from these arrangements to inform future value conversations as well.
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
Commonwealth Fund Report Details Pervasive Racial and Ethnic Disparities in US Health Care, Outcomes
April 18th 2024Using 25 health system performance indicators, the Commonwealth Fund 2024 State Health Disparities Report evaluated racial and ethnic disparities in health care and health outcomes both within and across US states and highlighted the urgent need for equitable health care policies and practices in the US.
Read More
The Biden administration recently launched the Global Health Security Strategy, a new effort to combat the spread of infectious diseases; lawmakers zeroed in on the risks of massive consolidation in health care during the first congressional hearing on the Change Healthcare hack; the FDA recently announced the recall of a pair of heart devices linked to numerous deaths and injuries.
Read More